Buzzing Biotech Stocks Today | Cytori Therapeutics (CYTX) | Xoma Corp (XOMA) | Agenus (AGEN)

2125
Cytori Logo

Today’s biotech market is a bit mixed. While there are big players like MannKind and Aoxing Pharmaceutical Company taking a nose dive, there are definitely a few stocks that are on the rise. Here are today’s buzzing biotech stocks…

Cytory Therapeutics Breaks From Lows

Cytori Therapeutics Inc (NASDAQ: CYTX)

Cytori Therapeutics stock hasn’t been doing too well in the market recently. After declining for more than 3 months now, the stocks seems to have finally reached support in the market. After touching at $0.58 per share three times, the stock has finally decided to move up; climbing to $0.65 today; a gain of 8.45%. I’m expecting to see this one start a slow and steady bullish trend. So, this may be a good time to start looking for dips if you’re considering purchasing shares of CYTX. Since the stock isn’t likely to break the $0.58 point, there’s currently far more upward potential than downward risk associated with Cytori in my oopinion.

XOMA Corp Stock Is Strong On High Volume

XOMA Corp (NASDAQ: XOMA)

XOMA stock is having a great day in the market today; trading bullish on high volume. The NASDAQ reports the 50 day volume average for the stock at 2,082,651 shares per day. However, so far today 3,100,589 shares have traded hands. As a result, the stock is climbing. Currently (3:02), XOMA is trading at $3.76 per share after a gain of 4.74%. The big question now is whether or not the growth is likely to last. In my opinion, I think we’re going to see a continued bullish trend for some time. With overwhelmingly bullish opinions of the stock among analysts, and investor sentiment up, this one is likely to grow. So, if you’re looking for an opportunity, it may be worthwhile to look for dips in XOMA.

Agenus Stock Is Trading Higher On Analyst Coverage

Agenus Inc (NASDAQ: AGEN)

Agenus stock is having a great day in the market today after Oppenheimer, a key analyst, initiated coverage on the stock. Upon the initiation of coverage on AGEN, Oppenheimer rated it with an “outperform” rating; giving the stock a price target of $14 and sending it 4.82% higher in the market so far today. This is another one that is opening the door to opportunities. Considering the recent news that Merck & Co. has extended its collaborative research term for the discovery and development of therapeutic antibodies to Merck proprietary immune checkpoints for the treatment of cancer, we are likely to see long run growth. The analyst coverage is simply ice on the cake. So, if you’re looking for something to get into that’s likely to lead to gains, consider watching AGEN for dips and buying opportunities.

Do You Know Of Any Others?

Are you tracking any biotech stocks that are gaining and likely to continue? Let us know in the comments below!

NO COMMENTS

LEAVE A REPLY